Nintedanib Accord

Nintedanib, the active ingredient in Nintedanib Accord, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It is indicated for certain fibrotic lung conditions and for use in combination therapy for non‑small cell lung cancer. GNH USA supplies Nintedanib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is an antifibrotic and anti‑angiogenic agent used in several serious lung disorders. - Idiopathic pulmonary fibrosis: slows the decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: helps preserve respiratory capacity and delays worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor control when used with other anticancer agents.

Nintedanib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: frequent loose stools, often manageable with antidiarrheal agents. - Nausea: feeling of sickness that may lead to reduced oral intake. - Vomiting: expulsion of stomach contents, sometimes accompanying nausea. - Abdominal pain: discomfort or cramping in the stomach area. - Decreased appetite: reduced desire to eat, potentially affecting weight. - Weight loss: unintended loss of body mass during treatment.

Serious or Rare Side Effects: - Elevated liver enzymes: indicates possible hepatic injury, requiring monitoring. - Bleeding events: increased risk of gastrointestinal or other hemorrhage. - Cardiovascular complications: such as hypertension or arterial thrombotic events. - Severe infections: opportunistic or serious bacterial infections. - Gastrointestinal perforation: rare but life‑threatening breach of the GI tract. - Interstitial lung disease exacerbation: worsening of underlying lung disease.

Before initiating therapy, clinicians should evaluate several safety parameters. - Liver function monitoring: check ALT, AST, and bilirubin regularly. - Bleeding risk assessment: avoid in patients with active ulcers or on strong anticoagulants. - Cardiovascular evaluation: screen for uncontrolled hypertension or recent cardiac events. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Drug interaction review: assess concomitant medications that affect CYP3A4 or P‑gp. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nintedanib interacts with several drug classes that can alter its exposure or increase adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise nintedanib plasma levels. - Potent P‑gp inhibitors (e.g., verapamil): can increase systemic exposure. - Anticoagulants and antiplatelet agents (e.g., warfarin, clopidogrel): heighten bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly increase exposure. - Moderate P‑gp inhibitors (e.g., amiodarone): require periodic liver function checks. - Acid‑reducing agents (e.g., proton pump inhibitors): may affect absorption, monitor efficacy.